Latest Conference Articles

In preliminary data from the trial evaluating dostarlimab, the results demonstrated that the clinical activity in patients with previously treated recurrent or advanced mismatch repair (MMR)-deficient endometrial cancer had an acceptable safety profile.

Treatment of ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors has a high out-of-pocket cost for patients, with substantial variation among them, according to a study.

An interview with Debra Richardson, MD, examined the phase 2 study that included niraparib with bevacizumab for patients with either a complete or partial response after upfront chemotherapy for advanced ovarian cancer.

In a population of patients newly diagnosed with ovarian cancer, researchers demonstrated that therapy is well tolerated among both patients who are BRCA-positive and -negative.

The combination of olaparib plus bevacizumab lead to a potentially meaningful improvement in progression-free survival versus olaparib alone in women with BRCA-mutated newly diagnosed ovarian cancer.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.

In patients with BRCA wild type carcinomas, treatment with veliparib was beneficial even at low homologous recombination deficiency scores compared with carboplatin and paclitaxel.

The addition of pazoparib to gemcitabine enhances anti-tumor activity, particularly for patients with platinum-resistant disease who derived the most benefit from combination therapy, even in the setting of receiving prior bevacizumab.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.

Researchers presented findings in conjunction with the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer on the phase 3 VELIA trial studying the safety of veliparib.

The CLIO trial evaluated olaparib single-agent therapy versus standard-of-care chemotherapy in platinum-sensitive recurrent epithelial ovarian cancer.

The objective of the study was to analyze whether USC would be uniquely sensitive to further interference of cell cycle regulation by Wee1 inhibition.

The objective of the study was to find whether niraparib improves PFS in patients with newly diagnosed advanced ovarian cancer after first-line (1L) platinum-based chemotherapy (CT).

XMT-1536, a first-in-class antibody-drug conjugate NaPi2B was well tolerated with no dose-limiting toxicities in patients with ovarian cancer and non-small cell lung cancer (NSCLC).

However, the magnitude of the progression-free survival (PFS) benefit is greatest when surgery achieved complete surgical debulking, specifically in the upfront setting.

The objective of the study was to analyze whether niraparib improves PFS in patients with newly diagnosed advanced ovarian cancer after response to first-line platinum-based chemotherapy.

Front-line use of vigil immunotherapy as maintenance in stage 3-4 ovarian cancer was well tolerated and demonstrated relapse-free survival clinical benefit.

Study findings suggest that veliparib added to carboplatin and paclitaxel during combination phase may provide anti-tumor activity versus carboplatin and paclitaxel alone.

Homologous recombination deficiency is not predictive of patient outcomes for veliparib-throughout versus control in patients with BRAC wildtype ovarian carcinomas.

Kirollos Hanna, PharmD, BCPS, BCOP, explains antibody drug conjugates and their method of action. This video was filmed at the Hematology/Oncology Pharmacists Association 2020 Meeting in Tampa, Florida.

Lesbian, gay, bisexual, transgender, and queer (LGBTQ) patients with cancer face specific barriers when seeking medical care, but pharmacists and other medical professionals can take specific steps to reduce the gaps in care.

Pharmacy Times will be on-site next week to provide coverage of the sessions, recaps of the panel discussions, and interviews with the experts.

Patients with ulcerative colitis have an increased risk of developing colorectal cancer (CRC), are diagnosed with less advanced CRC, and are at increased risk of death from CRC.

Patients diagnosed with Crohn disease and colorectal cancer (CRC) have a higher rate of mortality than patients without Crohn disease who are also diagnosed with CRC.

The discharge pharmacy service at West Virginia University (WVU) Medicine in Morgantown is intended to be a ‘patient first’ program that ensures patients receive the medications prescribed in hand, and that they remain adherent through medication counseling and followup.

Margetuximab plus chemotherapy showed positive results in a second pre-specified interim overall survival analysis for the phase 3 SOPHIA study.

Todd Brothers, PharmD, BCCCP, BCPS, clinical assistant professor, University of Rhode Island, discusses what patients should know about medications that cause hyperkalemia. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.

Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.

Since 2004, the FDA has approved different treatments for advanced prostate cancer, adding almost 2-3 indications per year for the past 15 years.

By entering clinical and disease characteristics into a learning algorithm, researchers were able to create an efficacy prediction for CDK inhibitors.